Passage Bio starts strategic review including M&A as FDA rules randomized registrational trial
Passage Bio starts strategic review including potential M&A as FDA requires randomized registrational trial for PBFT02 in FTD-GRN
- Company reported updated interim biomarker and safety data from its Phase 1/2 upliFT-D trial of PBFT02.
- FDA feedback indicated a randomized controlled registrational trial will be required for PBFT02 in FTD-GRN.
- Passage Bio engaged Wedbush PacGrow as advisor to explore strategic alternatives, including potential merger and acquisition options.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.